Skip to main content
SpringerLink
Log in

Briakinumab extension study highlights need for monitoring

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Langley RG, Williams D, Papp K, Olds M.Interim results from an open-label extension study of briakinumab for the treatment of moderate to severe psoriasis. 70th Annual Meeting of the American Academy of Dermatology: abstr. 4779, 16 Mar 2012. Available from: URL: http://www.aad.org

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Briakinumab extension study highlights need for monitoring. React. Wkly. 1397, 4 (2012). https://doi.org/10.2165/00128415-201213970-00012

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201213970-00012

Keywords

Search

Navigation